Notice of Intent to Publish a Funding Opportunity Announcement for Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed)
ID: 338909Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338909
Timeline
    Description

    The National Institutes of Health (NIH) is forecasting a funding opportunity for the establishment of a Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC) as part of its Somatic Cell Genome Editing (SCGE) program. This initiative aims to accelerate the development of genome editing therapeutic agents by facilitating Investigational New Drug (IND) application enabling studies, establishing regulatory approval pathways, and disseminating successful strategies for initiating first-in-human clinical trials. The total estimated funding for this opportunity is $2,000,000, with one award expected to be made, and the application due dates are anticipated in Summer 2022, following the publication of the Funding Opportunity Announcement in Spring 2022. Interested applicants can reach out to Dr. Marrah Lachowicz-Scroggins at 301-827-8229 or via email at SCGEprogram@od.nih.gov for further information.

    Point(s) of Contact
    Marrah Lachowicz-Scroggins, Ph.D.
    (301) 827-8229
    SCGEprogram@od.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for competitive revisions to support clinical trials in somatic cell genome editing, specifically under the funding opportunity RFA-RM-24-008. This initiative aims to expand the existing Somatic Cell Genome Editing program by soliciting applications from awardees with active U19 awards funded under RFA-RM-22-015, which previously did not allow clinical trials. The funding will facilitate first-in-human genome editing clinical trials, including essential preparatory activities such as patient recruitment, regulatory approvals, and the development of clinical trial designs. Interested applicants must submit their proposals by February 13, 2026, and can find additional information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Centers of Excellence in Genomic Science (CEGS) program, aimed at supporting innovative, interdisciplinary research in genomic science. This program seeks to establish academic centers that will develop transformative genomic approaches to address significant biomedical challenges, with a focus on integrating advanced technological and computational methods. Each award can provide up to $1.5 million per year for a maximum of five years, with potential renewal for an additional five years, and applications are due by June 23, 2025. Eligible applicants include a range of institutions such as higher education entities, nonprofits, and various government organizations, while foreign entities are not eligible. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a non-competitive funding opportunity for a cooperative agreement to support the Human Genetic Cell Repository (HGCR), with a focus on maintaining and distributing a diverse collection of human cell lines and DNA samples for biomedical research. The initiative aims to enhance the repository's capacity by acquiring new cell lines from diverse populations, ensuring ethical practices in sample collection, and promoting inclusivity in research efforts. This funding opportunity provides up to $1.75 million annually for a five-year project period, with applications due by June 10, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the funding announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-055.html.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovation in the application of genomic information in clinical care, particularly for populations experiencing health disparities. The initiative seeks to enhance understanding of how to effectively implement and share genomic technologies across diverse communities, including racial and ethnic minorities, underserved rural populations, and sexual and gender minority groups. With an expected total funding of approximately $1.5 million for fiscal year 2024, individual project budgets may reach up to $250,000. Interested applicants must submit their proposals by February 11, 2025, and can find additional details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the "Supporting Talented Early Career Researchers in Genomics" program, utilizing the R01 activity code. This initiative aims to provide financial support to early career researchers in the field of genomics, facilitating the development of innovative projects that contribute to the understanding of human genetics. The estimated total program funding is $2 million, with an award ceiling of $400,000 per project, and the application period is expected to open on December 18, 2024, with a closing date of February 28, 2025. Interested applicants should prepare their proposals in advance, as the estimated award date is set for December 31, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the establishment of Diagnostic Centers of Excellence (DCoE) as part of the Undiagnosed Diseases Network (UDN). The initiative aims to enhance the diagnostic journey for patients with undiagnosed diseases by creating a self-sustained network that provides expert diagnostic services and fosters scientific discovery, with a focus on utilizing genomics data. Eligible applicants will be clinical sites in the U.S. that can demonstrate the necessary infrastructure and expertise to conduct clinical evaluations and DNA sequencing, with the opportunity to enroll a minimum of five participants annually. Interested parties can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373 for further details. The program announcement is expected to be published in spring 2023, with applications due in early summer 2023, and the maximum period of performance for awarded projects will be five years.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.